Pro-Survival Lipid Sphingosine-1-Phosphate Metabolically Programs T Cells to Limit Anti-tumor Activity

Area of Science:

• Immunology
• Cell Biology
• Metabolic Regulation

Background:

• Sphingosine 1-phosphate (S1P) regulates T cell function, including lymphocyte circulation and differentiation.
• The role of intracellular S1P generated by Sphingosine kinase 1 (SphK1) in T cell functionality is not fully understood.
• Receptor-independent mechanisms of SphK1-mediated S1P signaling in T cells require elucidation.

Purpose of the Study:

• To investigate the impact of SphK1-generated intracellular S1P on T cell metabolism and function.
• To elucidate the molecular mechanisms linking SphK1 activity to T cell anti-tumor properties.
• To evaluate the therapeutic potential of targeting SphK1 for enhancing anti-tumor T cell therapy.

Main Methods:

• Generation and analysis of SphK1-deficient T cells.
• Assessment of T cell phenotype, mitochondrial respiration, and differentiation.
• Investigation of the correlation between SphK1, S1P, and PPARγ activity.
• Evaluation of T cell anti-tumor activity against murine melanoma in vivo.
• Combination therapy studies involving SphK1 inhibition and PD1 blockade.

Main Results:

• SphK1-deficient T cells exhibited a central memory phenotype with enhanced mitochondrial respiration and reduced regulatory T cell differentiation.
• A direct correlation was identified between SphK1-generated S1P and the activity of the lipid transcription factor PPARγ, which controls lipolysis.
• Genetic and pharmacologic inhibition of SphK1 improved T cell metabolic fitness and augmented their anti-tumor efficacy against melanoma.
• Combined inhibition of SphK1 and PD1 resulted in superior control of melanoma growth.

Conclusions:

• SphK1-generated intracellular S1P plays a critical role in regulating T cell metabolism and function.
• Targeting the SphK1/S1P pathway, particularly through inhibition, can enhance T cell-mediated anti-tumor immunity.
• Limiting SphK1/S1P signaling presents a promising strategy for improving the efficacy of adoptive T cell therapies in cancer treatment.